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Abstract: This review aims to discuss the varied types of inhibitors of biotin-dependent carboxylases, with an emphasis 
on the inhibitors of pyruvate carboxylase. Some of these inhibitors are physiologically relevant, in that they provide ways 
of regulating the cellular activities of the enzymes e.g. aspartate and prohibitin inhibition of pyruvate carboxylase. Most  
of the inhibitors that will be discussed have been used to probe various aspects of the structure and function of these  
enzymes. They target particular parts of the structure e.g. avidin – biotin, FTP – ATP binding site, oxamate – pyruvate 
binding site, phosphonoacetate – binding site of the putative carboxyphosphate intermediate.  
Keywords: Pyruvate carboxylase, biotin-dependent enzyme, avidin, biotin, nucleotide inhibitors, acetyl coenzyme A, allosteric 
inhibitors, chlorothricin.  
INTRODUCTION 
 Pyruvate carboxylase (PC, EC 6.4.1.1), a regulatory 
metabolic enzyme responsible for replenishing the interme-
diates of the TCA cycle and catalyzing the first committed 
step in gluconeogenesis, is found in a wide variety of  
organisms including bacteria, fungi, plants, invertebrates and 
vertebrates [1]. Eukaryotic PC is generally located in the 
mitochondria with the exception of yeast, where the two iso-
forms of PC (Pyc1 and Pyc2) are encoded by different genes, 
and fungal PC, both of which are localized in the cytoplasm 
[2].  
 Abnormalities in PC activity and regulation have been 
associated with the occurrence of Type II diabetes [3] result-
ing in impaired-glucose tolerance and insulin insensitivity 
[4]. In pre-diabetic patients, pancreatic islets compensate for 
the escalating insulin-resistance by increasing glucose-
stimulated insulin secretion (GSIS) [3, 5]. Studies performed 
by Jensen and co-workers [6] proposed that GSIS activity 
was tightly correlated with the PC-catalyzed anaplerotic flux 
through the TCA cycle and subsequent cycling of pyruvate 
through the malate-pyruvate shuttle. Recently, the use of 
small interfering RNA (si-RNA) to partially suppress PC 
activity in INS-1 83/13-derived cell lines by Hasan et al. [7] 
demonstrated that decreases in GSIS were directly propor-
tional to decreases in PC activity. Furthermore, Liu et al. [8] 
previously observed a 2-fold increase in in vivo PC ?-cell 
activity and GSIS in obese, non-diabetic, insulin-resistant 
Zucker fatty rats as compared to non-insulin resistant Zucker 
lean rats. Inhibition of PC by the addition of phenylacetate 
resulted in not only a marked decrease in PC activity, but  
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also a corresponding decrease in GSIS. The decreased PC 
activity and expression observed in the islets of diabetic rats, 
which are insulin resistant and show little GSIS [9, 10]  
further suggests that PC plays an important role in both GSIS 
and ?-cell adaptation to insulin resistance in fully function-
ing pancreatic cells. While the mechanism by which PC  
activity regulates and enhances GSIS is not completely un-
derstood, it has been proposed by MacDonald [11] and oth-
ers [12] that the metabolic cycling of pyruvate through PC 
and the subsequent formation of anaplerotic by-products, 
including NADPH, aids in modulating GSIS in pancreatic 
islets.  
 Abnormally, high hepatic PC activity was initially  
observed in diabetic rats [5, 9, 10]. Deterioration of the GSIS 
pathway, due in part to chronic exposure to fatty acids,  
decreases the ability of the ?-cells to secrete insulin, and  
can lead to the development of Type II diabetes [5, 13]. 
Metabolic flux through hepatic PC is normally attenuated  
by the insulin-signaling pathway [14], but is increased in 
Type II diabetics resulting in raised hepatic glucose produc-
tion [3, 13]. The metabolic abnormalities in the regulation 
and activities of PC associated with Type II diabetes make 
PC an attractive molecular target for the development of  
new therapeutic agents for the treatment of this progressive 
disease.  
 Fan and co-workers [15] have recently established a con-
nection between PC activity and the “mitochondria dysfunc-
tion” observed in malignant lung cancer [16]. 13C isotopomer 
analysis by NMR revealed direct evidence for increased  
glycolytic activity in malignant tumor cells and further 
demonstrated that both PC expression and activity, in vivo, 
were activated in human lung cancer. Previously, a nearly 
100-fold increase in PC’s anaplerotic activity was observed 
in in vitro studies of breast cancer cells [17] and PC’s  
gluconeogenic activity was found to be elevated in hepatic 
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tumors in rats [18], demonstrating that increased PC activity 
correlates with the uncontroled proliferation of tumor cells. 
Therefore, the selective inhibition of PC activities in tumor 
cells may prove to be a viable, alternative target for newly 
emerging antiproliferative cancer treatments.  
 The connection between abnormal PC activity, Type II 
diabetes and cancer substantiates the importance of under-
standing the structure, mechanism and inhibition of this 
regulatory enzyme. The native structure of PC from most 
sources is an (?)4 tetramer, where the biotin carboxylase 
(BC), carboxyl transferase (CT), biotin-carboxyl carrier pro-
tein (BCCP) and allosteric, or tetramerization, domains are 
contained on a single polypeptide chain, although it has been 
shown that some bacterial PCs have an (??)4 structure with 
the BC domain forming the ? subunit and the CT and BCCP 
domains forming the ? subunit. Recently, the structures of 
PC holoenzymes from Rhizobium etli [19] and Staphylococ-
cus aureus [20, 21] have been determined. These structures, 
along with site directed mutagenic studies [19], revealed that 
the covalently attached biotin moves between the BC domain 
of one subunit to the CT domain of a neighbouring subunit 
located on an opposing polypeptide chain [19] thus giving 
rise to a distinctive form of intersubunit catalysis. Further-
more, acetyl CoA, an allosteric activator of PC from several 
sources, binds in the allosteric domain [19] and appears to 
facilitate the interdomain movement of the BCCP and cova-
lently attached biotin. While the activity of most vertebrate 
PCs is highly regulated by acetyl CoA, PC from some bacte-
rial and fungi sources have no acetyl CoA dependence [1].  
 Similar to other biotin-dependent carboxylases, including 
acetyl CoA carboxylase, propionyl CoA carboxylase and 
methyl malonyl CoA carboxylase, PC catalyses the carboxy-
lation of pyruvate in two distinct steps which occur at  
discrete active sites (Fig. 1A). Biotin, which is covalently 
attached to the ?-NH2 of a strictly conserved lysine residue 
located at the C-terminal end of the BCCP, is carboxylated at 
the N-1 position in the BC domain via the ATP-dependent 
activation of bicarbonate and formation of a putative  
carboxyphosphate intermediate [22]. Acting as a mobile  
carboxyl carrier, carboxybiotin is then translocated from the 
BC domain to a neighbouring CT domain where it is decar-
boxylated (Fig. 1B). Prior to carboxylation, the transfer of a 
proton from pyruvate to biotin, facilitated by a strictly con-
served Thr residue, is proposed to aid in the formation the 
nucleophilic enol-pyruvate [23]. The carboxyl group is then 
transferred to the nucleophilic substrate, forming oxaloace-
tate (Fig. 1B).  
 A wealth of structural and kinetic data has been reported 
for PC, contributing greatly to a detailed description of the 
PC mechanism. The aim of this review is to focus specifi-
cally on the inhibition of PC as it relates to both the devel-
opment of the current mechanistic model of PC activity and 
the physiological regulation of the enzyme activity (Table 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Overall PC-catalysed reaction. A) Biotin carboxylation occurring in the BC domain. B) Carboxyl transfer step occurring in the CT 
domain. 
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Table 1.  Summary of the Different Intermediates and Inhibitors of Pyruvate Carboxylase Activities 
Inhibition of PC through Interactions with Other Proteins 
Name Structure Function/Mode of Inhibition References 
Avidin • Tetrameric protein • Binds to the biotin covalently attached to the 
BCCP of PC with high affinity 
[31-36] 
Prohibitin 
(Phb1) 
• Mitochondrial  
chaperone protein 
• Inhibition of anaplerotic activities of PC 
• Mechanism of Phb1 inhibition unclear 
[48-50] 
Inhibition of PC through Interactions with the Biotin Carboxylase (BC) Domain 
Name Structure Function/Mode of Inhibition References 
Carboxyphosphate 
 
O P
O
O
O
O
O
 
• Putative intermediate formed during the ATP-
dependent carboxylation of biotin by bicarbonate 
[19, 22, 23] 
 
Carbamoyl  
phosphate 
 O P
O
O
O
O
NH2
 
• Structural analogue of carboxyphosphate 
• Substrate for ADP phosphorylation reaction 
 
[23, 38, 65] 
Phosphonoacetate 
 
O P
O
O
C
H2
O
O
 
• Competitive inhibitor with respect to ATP 
• Inhibition results from the increased strength of 
the C-CH2-P bond 
 
[58, 59] 
 
Formycin A-5’-
triphosphate (FTP) 
 
O
OHOH
OPO
O
O
HN
N N
N
H2N
POPO
O
O
O
O
 
• Fluorescent analogue of ATP used in structure-
function studies 
• Competitive inhibitor with respect to ATP for 
chicken liver PC 
• Can act as substrate for PC from some sources 
albeit at a greatly reduced rate 
 
[64-66] 
 
5’-adenosine mono-
phosphate  
(5’-AMP) 
 
O
N
OHOH
OPO
O
O
N
N
N
H2N
 
• Competitive inhibitor with respect to ATP 
• Less effective inhibitor than adenosine possibly 
due to active site interactions with negatively 
charged phosphoryl group  
 
[33, 62] 
 
3’, 5’-cyclic adenosine  
monophosphate 
(3’, 5’- cyclic AMP) 
 
O
N
OHO
O
P
O
O
N
N
N
NH2
 
• Competitive inhibitor with respect to ATP 
• Similar to 5’-AMP, number of phosphoryl 
groups has greater effect on inhibition/nucleotide 
binding than positioning of ?-phosphate 
 
[33, 62] 
 
Nucleotides and  
nucleosides (GTP, 
UTP, CTP, TTP, ITP) 
 • See Figure 4 for complete structures  
 
• Competitive inhibitors with respect to ATP 
[33, 62] 
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Table 1. contd…. 
Inhibition of PC through Interactions with the Biotin Carboxylase (BC) Domain 
Name Structure Function/Mode of Inhibition References 
ATP-?-S 
O
N
OHOH
OPO
O
O
N
N
N
H2N
POPO
S
O
O
O
 
• Non-hydrolysable analogue of ATP 
• Used extensively in structure-function studies 
[19] 
?,?-methylene diphos-
phate 
 (Ap(CH2)p) 
 
O
N
OHOH
OP
H2
C
O
O
N
N
N
H2N
PO
O
O
 
• Analogue of ADP, competitive inhibitor with 
respect to ATP 
• Enzyme has higher affinity for analogue as com-
pared to ADP 
• Inhibition similar to ATP analogues 
 
[58, 62] 
 
adenosine 5’-
phosphosulfate 
(APS) 
 
O
N
OHOH
OPO
O
O
N
N
N
H2N
SO
O
O
 
• Analogue of ADP, competitive inhibitor with 
respect to ATP 
• Not phosphorylated in reverse reaction of BC 
domain  
 
[58, 62] 
 
Inhibition of PC through Interactions with the Carboxyl Transferase (CT) Domain 
Name Structure Function/Mode of Inhibition References 
Pyruvate 
 O
O
O  
• Substrate for the carboxyl transfer reaction 
• Enolisation of pyruvate promotes carboxylation 
[19, 22, 23] 
 
Oxamate 
H2N
O
O
O  
• Structural analogue of pyruvate 
• Coordinates to Mn2+ or Zn2+ metal center in the  
• CT domain active site 
• Physiologically inhibits gluconeogensis  
[35, 69-71] 
 
Oxalate 
 
O
OO
O
 
• Strong metal chealator 
• Binds to metal center similar to oxamate 
• Physiological inhibition of anaplerosis  
 
[35, 62,  
74-80] 
 
Pyruvate derivatives 
 O
O
O
R
 
• R = -F, -Cl, -Ph, -OH 
• Competitive with respect to pyruvate 
• Some derivatives can act as carboxyl acceptors 
[35, 81-84] 
 
3-chloro-1,2-
propanediol 
(CPD) 
 
Cl
OH
OH
 
• Carcinogenic choloropropanol 
• Inhibits gluconeogenesis through direct  
inhibition of PC 
  [82] 
 
Univalent and divalent 
cations 
 
 • Replaces active metals in both the CT and BC 
domains 
• Physiological regulation of PC activity through-
feedback inhibition 
[69, 85-89] 
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Table 1. contd…. 
Inhibition of PC through Interactions with the Allosteric Domain 
Name Structure Function/Mode of Inhibition References 
L-aspartate 
 
O
O
NH2
O
O
 
• Allosteric inhibitor of microbial and fungal PC 
• Physiological regulatory feedback inhibition in 
response to TCA intermediates 
• Competitive inhibitor with respect to acetyl CoA 
 
[90-109] 
 
L-glutamate 
 
O
NH2
O
O
O
 
• Allosteric inhibitor of PC from vertebrates 
• Non-competitive inhibitor with respect to acetyl 
CoA and competitive with respect to pyruvate 
• Similar physiological function as aspartate 
[90, 110-
111] 
 
?-ketoglutarate 
 
O
O
O
O
O  
• PC from various sources inhibited  
• Physiological ratios of glutamate, acetyl CoA 
and ?-ketoglutarate to regulate mitochondrial  
activities 
[90, 93, 
105, 112-
115] 
 
chlorothricin 
HO
O O
O
CH3
COOH
CH3
OR
O
OH
O
OHOO
O CH3
Cl
H3C
R=
 
• Macrolide-type antibiotic  
• Inhibits PC activity through antagonistic interac-
tions with acetyl CoA 
• No inhibition observed in the absence of acetyl 
CoA   
 
[116-122] 
 
benzoate/ benzoyl CoA 
 
OH
O
O
S CoA
 
• Conversion of benzoate to benzoyl CoA reduces 
availability of acetyl CoA 
 
[113, 123, 
124] 
 
phenylacetate 
 
OH
O
S
CoA
O
 
• Conversion of phenylacetate to phenylacetyl 
CoA reduces acetyl CoA 
• Phenyl acetyl CoA directly inhibits PC activity 
 
[8, 93, 100, 
125-127] 
 
acyl CoA derivatives 
 CoA
S
H3C
O
n  
• Inhibition occurs when n = 4-10 in some sources 
 
[110] 
 
methylmalonyl CoA 
 CoA
S
O
O
O
 
• Strong competitive inhibitor with respect to 
acetyl CoA in chicken and rat liver PC 
[36, 110] 
 
acetoacetyl CoA 
 CoA
S
O
H3C
O
 
• Binds at a unique allosteric site 
• Noncompetitive inhibition with respect to all 
substrates and acetyl CoA 
[115, 129] 
 
 
While most of the inhibitors discussed herein have been used 
to probe various aspects of PC structure and function, the 
physiological relevance of several of these inhibitors have 
also been examined in hopes of further understanding PC’s 
role in the pathogenesis of Type II diabetes. 
INHIBITION THROUGH INTERACTION WITH 
OTHER PROTEINS 
Inhibition by Avidin 
 Avidin, a protein abundant in egg whites, binds biotin 
with a KD on the order of 10
-15 M [24]; therefore, egg white-
rich diets have been used to induce experimental biotin defi-
ciencies in animals [25]. A tetrameric protein (MW 63 kDa), 
avidin is approximately cuboid in shape and contains one 
biotin-binding site per subunit, with the biotin-binding sites 
arranged in pairs on opposite faces of the cuboid structure 
[26, 27] (Fig. 2). The potential use of avidin for the purifica-
tion of biotinylated enzymes was quickly recognized; how-
ever, the affinity of avidin for biotin was so high that elution 
of the enzymes was problematic. By dissociating avidin into 
its constituent monomers before immobilizing them on 
CNBR-Sepharose, thereby effectively reducing the affinity 
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of avidin for biotin, avidin could be used for the selective 
isolation and purification of biotin-containing enzymes [28-
30]. 
 
 
Fig. (2)(A). Model of the quaternary structure of tetrameric avidin, 
with one biotin molecule (in green) bound to each monomer. The 
polypeptide backbones of the four monomers are each coloured 
differently. Reproduced from [27] B) Diagramatic representation of 
the structure of tetrameric avidin, showing the arrangement of the 
biotin-binding sites in pairs on opposite sides of the cuboid struc-
ture. The pair of biotin-binding sites on the opposite 55 Å x 55 Å 
faces of the molecule are shown as overlapping dotted circles. Re-
produced with permission from Green, N.M., Konieczny, L., Toms, 
E.J. and Valentine, R.C. (1971) Biochem J. 125: 781-791 [26] and 
the Biochemical Society (http://www.biochemj.org). 
 The extremely high affinity of avidin for biotin also 
makes it a potent inhibitor of biotin-dependent enzymes. The 
first report of inhibition of PC by avidin dates back to 1960 
[31] and, subsequently, Scrutton and co-workers used avidin 
as a probe of the enzymatic mechanism [32, 33]. In these 
experiments, incubation of the enzyme with avidin was 
shown to completely inhibit both [14C]pyruvate:oxaloacetate 
and 32Pi:ATP isotopic exchange reactions [32], demonstrat-
ing the direct participation of biotin in these reactions. 
Avidin only inhibits the [14C]ADP:ATP isotope exchange by 
about 10%, indicating that biotin is not directly involved in 
this reaction [33]. 
 Assuming the avidin-inhibition of PC to be irreversible, 
Scrutton and Utter [33] also performed the first reported ki-
netic investigation of the inhibition. Under pseudo-first order 
conditions, analysis of the reaction order gave a stoichiome-
try of avidin: PC binding of 1.4, indicating that approxi-
mately one avidin molecule binds per enzymic PC tetramer 
[33]. In an extension of these early kinetic studies, Duggleby 
et al. [34] examined the kinetics of avidin-PC inhibition us-
ing methodologies developed for the study of slow, tight-
binding inhibitors. Consequently, PC was added to reaction 
mixtures containing fixed, saturating concentrations of the 
substrates for pyruvate carboxylation, acetyl CoA and vary-
ing concentrations of avidin. By using the coupling enzyme 
malate dehydrogenase and monitoring the reduction of 
NADH [34], the development of the inhibition of the reac-
tion was directly determined from the decrease in the initial 
rates over the duration of the assay. The mode of inhibition 
of PC by avidin could be sufficiently explained using a 
scheme where the slow development of the inhibition was 
due to the binding of avidin to PC, rather than the enzyme 
undergoing a slow conformational change [34]. The second 
order rate constant for avidin binding was determined to be 
1.49 ? 105 M-1s-1, which is several orders of magnitude lower 
than the calculated diffusion-controled constant of 1.7 ? 108 
M-1s-1 and about 500 times lower than that for the binding of 
free biotin to avidin [24], suggesting that strong steric factors 
govern the rate of avidin binding to the covalently attached 
biotin in PC. In the structures of Staphylococcus aureus PC 
where the position of biotin has been determined [20, 21], it 
is bound either in the active site of the CT domain or in a 
pocket outside of the CT domain. Its other possible position 
is in the active site of the BC domain. In any case, the biotin 
does not appear to be easily accessible to the binding sites of 
avidin. 
 The inhibition of PC by avidin was shown to be at least 
partially reversible, as determined by the ability to reactivate 
the enzyme initially incubated with a 2-5 fold molar excess 
of avidin through the addition of 3000-5000 fold molar ex-
cess of free biotin [34]. Owing to the very slow nature of the 
reactivation process, the time course of these experiments 
was 16 hours during which there was an approximately 75% 
loss of enzymic activity in control solutions of PC that did 
not contain avidin. However, this loss of activity did not ac-
count for the small degree of reactivation that was observed 
in the experimental sample and, thus, it was proposed that 
PC in complex with avidin also underwent an inactivation 
reaction [34]. Based on kinetic analysis of the reactivation of 
the PC-avidin complex in the presence of free biotin, the 
reactivation occurred at a rate (6-10 ? 10-5 s-1) that was about 
4-8 fold greater than that for the inactivation of the free en-
zyme (7.6 ? 10-6 s-1) and for the dissociation of the avidin 
from PC (1.42 ? 10-5 s-1) [34]. This dissociation rate constant 
of avidin from the tethered biotin is about 160 times greater 



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than that for the dissociation of avidin and free biotin [24]. 
Thus the dissociation constant for the avidin-PC complex is 
10-10 M, which is five orders of magnitude greater than that 
determined for the avidin-biotin complex. One of several 
factors contributing to the lower affinity of the biotinylated 
enzyme for avidin, as compared to free biotin, may be the 
covalent attachment of biotin to the side-chain of a con-
served lysine residue in the BCCP domain of PC via the 
formation of an amide bond with the carboxyl group of bio-
tin. In free biotin, the carboxyl oxygen forms two hydrogen 
bonds with residues in the biotin-binding site of avidin [26], 
which could partially account for some of the decreased af-
finity. Even so, the large steric effect introduced by the at-
tachment of the biotin to the enzyme, which subsequently 
reduces the ability of avidin to bind to the covalently at-
tached biotin as tightly as free biotin, is most likely respon-
sible for increasing the overall dissociation constant deter-
mined for the PC-avidin complex.  
 In addition to measuring the simple kinetics of avidin-
inhibition of PC, Scrutton and co-workers also examined the 
effect various nucleotides had on the inhibition. It was found 
that saturating concentrations of not only ATP, but also 
ADP, 3’-AMP and 5’-AMP completely protected PC from 
avidin inhibition [33]. The protective effect of these latter 
two nucleotides, which do not promote biotin carboxylation, 
strongly suggests that nucleotide binding to PC is liable to 
reduce the accessibility of the tethered biotin to avidin by 
inducing conformational changes which place biotin in the 
BC domain. On the other hand, substrates and products of 
the CT domain active site enhance the rate of avidin inhibi-
tion of PC by approximately 33% and 78% with saturating 
pyruvate and oxaloacetate, respectively [35], indicating the 
possibility that the binding of these molecules to PC in-
creases the exposure of biotin to avidin by inducing the 
movement of the tethered biotin from the BC domain to the 
CT domain.  
 The effect of the allosteric activator, acetyl coenzyme A 
(acetyl CoA), on the avidin inhibition of PC is more compli-
cated. The rate of PC inactivation due to avidin- inhibition is 
increased approximately 8-fold when acetyl CoA concentra-
tions were kept between 10 and 200 μM, but at concentra-
tions of above 200 μM, the rate of inactivation decreased 
[36]. It is interesting to note that the acetyl CoA concentra-
tions which resulted in an increased rate of PC inactivation 
by avidin correspond to the same concentrations where ace-
tyl CoA is most potent as an activator [36]. These results 
further support the previous conjecture that a conformational 
change in the PC structure, induced by the binding of the 
allosteric activator and CT domain substrates, increases the 
exposure of the tethered biotin to avidin. At higher concen-
trations of acetyl CoA, there is a counteracting conforma-
tional change, possibly due to the non-productive, partial 
occupation of the nucleotide binding site [36], which imparts 
a protective effect against avidin-inhibition, similar to that 
observed in the presence of the various nucleotides. These 
early avidin- inhibition studies were the first indication that 
the movement of the BCCP and tethered biotin is dependent 
on the presence of substrates and activators. Later kinetic 
studies [23, 37, 38] and crystal structures [19, 20] confirmed 
that the presence of BC and CT domain substrates and ana-
logues dictate the location of the tethered biotin. 
 The stoichiometry of the avidin-PC binding was deter-
mined to be 1 mol /mol from both the kinetic measurements 
of Scrutton and Utter [33] and titration experiments which 
measured the displacement of 2-(4’-hydroxyazobenzene) 
benzoic acid from the biotin binding sites in avidin by PC 
[34]. Electron microscopy studies of PC revealed that the 
enzyme subunits were arranged such that there appeared to 
be an active site cleft running along the long axes with the 
four subunits arranged in a tetrahedron-like configuration, as 
shown in Fig. (3A) [39]. It was difficult to envisage how one 
tetrameric avidin molecule could bind the four biotins of one 
tetrameric PC molecule, leading to the conclusion that het-
ero-oligomers of avidin and PC may form. When Johannssen 
et al. [40] examined the complexes of chicken liver PC and 
avidin formed from varying ratios of the two molecules un-
der the electron microscope, they observed the formation of 
chain-like hetero-oligomers when the avidin: PC ratio was 
between 2:1 and 1:2 in the presence of acetyl CoA (Fig. 3B). 
Rohde et al. [41] obtained similar results using yeast PC. A 
proposed model of these hetero-oligomers indicated that 
avidin may act as a “glue,” thereby joining two PC tetramers, 
with the biotin-binding sites on one face of the avidin 
tetramer binding two biotins from one PC molecule and the 
binding sites on the opposite face of the avidin molecule 
binding two biotins from another PC tetramer (Fig. 3C) [40]. 
When the avidin:PC ratio was 9:1, PC-avidin complexes 
which contained two avidin tetramers for every PC tetramer 
were observed to be bound in a similar arrangement to those 
previously described (Figs. 3D and E) [40]. X-ray crystal 
structures of the PC holoenzyme from a variety of sources 
have confirmed the arrangement of pairs of biotins on oppo-
site faces of the PC tetramers [19-21]. 
 Attwood et al. [42] showed that when PC was incubated 
with avidin in a 1:1 ratio in the absence of acetyl CoA, only 
a small number of shorter hetero-oligomers and few intact 
PC tetramers were formed. In addition, the complexation of 
PC with avidin was shown to stabilise the tetrameric struc-
ture of the enzyme, protecting it against dilution- dissocia-
tion [43]. This stabilization was further enhanced by the 
presence of acetyl CoA, suggesting that the binding of the 
activator induces PC to adopt a conformation that not only 
facilitates the binding of avidin, thereby forming the hetero-
oligomers, but also aids in the stabilization of the PC 
tetramer. The proposed conformational and catalytic effects 
of acetyl CoA binding to PC have been recently demon-
strated in the X-ray crystallographic structure determined for 
the PC holoenzyme from Rhizobium etli, which is activated 
in the presence of acetyl CoA [19]. The R. etli PC structure 
suggests the possibility that the binding of the allosteric acti-
vator promotes critical, global domain rearrangements which 
facilitate inter-subunit catalysis via the movement of the 
tethered biotin from the BC domain of one subunit to the CT 
domain of the neighbouring subunit, [19]. Subunits without 
acetyl CoA bound in the allosteric domain appear to adopt a 
different conformation such that the inter-subunit catalysis 
would be difficult [19]. These large conformational changes 
induced by acetyl CoA binding could, in part, explain the 
effect that acetyl CoA has on the formation of the PC-avidin 
hetero-oligomers. Interestingly, high concentrations of pyru-
vate were also determined to have a similar effect on hetero-
oligomer formation [42], although no structure of PC has yet 
been obtained at these concentrations of pyruvate.  
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 Avidin has proven to be an extremely useful tool for the 
examination of the biotin-dependence of the PC mechanism. 
It has permitted the investigation of tethered biotin move-
ment induced by the binding of substrates and inhibitors and 
has suggested a possible structural role for the activator  
in the stabilization of the quaternary enzyme structure. In 
addition, the avidin-inhibition studies of PC enabled the  
approximate determination of structural aspects of the 
tetrameric enzyme, including the positioning of the biotins 
on the subunits, which was especially important prior to  
X-ray crystal structure determination.  
Fig. (3)(A). Model of the tetrahedron-like arrangement of the subunits of PC derived from electron microscopic studies of the enzyme. Re-
produced with permission from Mayer, F., Wallace, J.C., Keech, D.B. Further electron microscope studies on pyruvate carboxylase. Eur. J. 
Biochem. 1980; 112: 265-272 [39] (Wiley-Blackwell). B) Electron micrograph of hetro-oligomers formed between chicken liver PC and 
avidin at a ratio of avidin:PC of 1:2, in the presence of 0.25 mM acetyl CoA. The bar represents 40 nm. Reproduced with permission from 
Johannssen, W., Attwood, P.V., Wallace, J.C., Keech, D.B. Localization of the active site of pyruvate carboxylase by electron microscopic 
examination of avidin-enzyme complexes. Eur. J. Biochem. 1983; 133: 201-206 [40] (Wiley-Blackwell). C) Model of a hetero-oligomer of 
avidin and PC, with the PC subunits shown in white and the avidin tetramers shown as grey cuboids, linking two PC tetramers together. Jo-
hannssen, W., Attwood, P.V., Wallace, J.C., Keech, D.B. Localisation of the active site of pyruvate carboxylase by electron microscopic 
examination of avidin-enzyme complexes. Eur. J. Biochem. 1983; 133: 201-206 [40] (Wiley-Blackwell). D) Electron micrograph of complex 
between a chicken liver PC tetramer and two avidin molecules, at a ratio of avidin:PC of 9:1. The avidin molecules are indicated by filled 
triangles and the PC subunits by open triangles. The bar represents 16 nm. Johannssen, W., Attwood, P.V., Wallace, J.C., Keech, D.B.. Lo-
calisation of the active site of pyruvate carboxylase by electron microscopic examination of avidin-enzyme complexes. Eur. J. Biochem. 
1983; 133: 201-206 [40] (Wiley-Blackwell). E) Model of the complex between a PC tetramer and two avidin molecules with the PC subunits 
shown in white and the avidin tetramers shown as grey cuboids. Johannssen, W., Attwood, P.V., Wallace, J.C., Keech, D.B.. Localization of 
the active site of pyruvate carboxylase by electron microscopic examination of avidin-enzyme complexes. Eur. J. Biochem. 1983; 133: 201-
206 [40] (Wiley-Blackwell). 
 
 
 
B 
 
 
C 
 
 
 
D       E 
 
16    The Open Enzyme Inhibition Journal, 2010, Volume 3 Zeczycki et al. 
Inhibition by Prohibitin  
 The prohibitins, Phb1 and Phb2, belong to a family of 
highly conserved membrane-associated proteins which had 
initially been identified as having putative regulatory roles in 
eukaryotic cell proliferation, apoptosis, tumor suppression 
and transcriptional activities [44, 45]. Furthermore, the  
localization and abundance of Phb1 at the inner mitochon-
drial membrane [46] suggests its importance as a membrane-
bound chaperone protein which aids in stabilizing newly 
synthesized or imported mitochondrial proteins [47].  
Sequence homology with other chaperone proteins, such  
as HSP60, and computational predictions suggest the  
N-terminal, transmembrane-spanning helix in Phb1 may 
anchor the protein to the inner-mitochondrial membrane 
[48]. Within the mitochondria, Phb1 and Phb2 form  
high-molecular weight, ring-shaped Phb1/Phb2 complexes 
which further facilitate their function as chaperone proteins 
[45]. 
 Phb1 and PC were identified as two of several mitochon-
drial proteins isolated from lipolytically stimulated 3T3-L1 
adipocyte lipid droplets [49], demonstrating that adipocytes 
contain lipid metabolic enzymes and proteins. In vivo and in 
vitro studies using mice adipocytes revealed that Phb1 is a 
potent, specific inhibitor of PC and, through this inhibition, 
attenuates both fatty acid and insulin-stimulated glucose oxi-
dation [50]. The insulin-stimulated release of 14CO2 from 
uniformly labeled 14C-glucose was markedly inhibited in the 
presence of 2 nM prohibitin and a Ki of approximately 4 nM 
for Phb1 inhibition of PC in vivo was determined. Inhibition 
of fatty acid oxidation in the presence of Phb1 in the mouse 
adipocytes was most likely due to the lack of available ox-
aloacetate resulting from the almost complete inhibition of 
PC. By monitoring the incorporation of NaH14CO3 into ox-
aloacetate, Vessal and co-workers further established that 
Phb1 potently inhibited (Ki ? 5 nM) PC isolated from the 
adipocyte lysate [50]. While the mechanism of PC inhibition 
by Phb1 is not clearly understood, both in vivo and in vitro 
studies indicate that Phb1 that has been translocated into the 
mitochondria effectively inhibits anaplerosis through interac-
tions with PC. Whether this inhibition has any physiological 
relevance, or if Phb2 and the Phb1/Phb2 complex exhibit the 
same inhibitory effects on PC remains uncertain [48].  
INHIBITION OF THE BIOTIN CARBOXYLASE  
DOMAIN 
 The reaction catalysed in the BC domain, namely the 
ATP-dependent carboxylation of biotin by bicarbonate, is 
common to biotin-dependent carboxylases, with the excep-
tion of transcarboxylase [22]. Recent studies have focused 
on the inhibition of the biotin carboxylase subunit of acetyl 
CoA carboxylase from E. coli, which exists as a homodimer 
in solution and utilizes free biotin as a substrate [51].  
Reaction-based intermediate analogues [52, 53] and small 
molecules, determined from a fragment-based screening ap-
proach [54-56], have been shown to successfully inhibit  
E. coli biotin carboxylase. Since many of the examples of 
biotin carboxylase inhibition have been extensively dis-
cussed in a previous review [57], only those studies which 
involve the inhibition of the biotin carboxylase domain in the 
context of the PC holoenzyme will be discussed here. 
Intermediate and Substrate Analogue Inhibitors 
 Ashman and Keech [58] used analogues of the putative 
carboxyphosphate intermediate to probe the reaction mecha-
nism of the BC domain in PC. In steady-state kinetic ex-
periments, phosphonoacetic acid exhibited noncompetitive 
inhibition with respect to MgATP (Ki = 0.5 mM) when the 
initial rates of oxaloacetate formation were determined using 
PC from sheep kidney. Similarly, phosphonoacetate was a 
competitive inhibitor with respect to MgATP (Ki = 7.8 ± 1.8 
mM) and a noncompetitive inhibitor with respect to HCO3
- 
for the biotin carboxylation reaction catalysed by E. coli bio-
tin carboxylase [59]. It was proposed that the inhibition was 
due, in part, to the replacement of the highly labile C-O-P 
bond in carboxyphosphate with a stable C-CH2-P bond. 
Since phosphonoacetic acid is an isosteric and isoelectronic 
analogue of carboxyphosphate, these inhibition studies lent 
further support to the proposed mechanism whereby biotin 
carboxylation occurs via the reversible formation of the 
unstable, mixed-anhydride intermediate. 
 Carbamoyl phosphate, a structural analogue of carboxy-
phosphate, will directly phosphorylate ADP in reactions 
catalyzed by acetyl CoA carboxylase from E. coli [60] and 
PC [58], allowing for the examination of the partial reverse 
reaction of the BC domain without complications due to bio-
tin carboxylation. Inhibition of the PC-catalyzed phosphory-
lation of ADP with carbamoyl phosphate [38] and the bicar-
bonate-dependent ATP cleavage [61] was observed in the 
presence of oxamate, a substrate analogue of pyruvate (see 
inhibition of the CT domain reactions). Even though ox-
amate has been shown to bind in the CT domain, a hyper-
bolic, non-competitive inhibition with respect to carbamoyl 
phosphate was observed in those reactions catalyzed by PC 
from chicken liver [38]. Correspondingly, the addition of 20 
mM of oxamate resulted in a 98% reduction in the rate of the 
PC-catalyzed bicarbonate-dependent ATP cleavage [61]. The 
non-competitive nature of the oxamate inhibition of the BC 
domain reactions further confirmed initial avidin inhibition 
studies [34] and later kinetic studies by Goodall et al. [37], 
which suggested that the binding of oxamate in the CT do-
main active site induces the translocation of biotin from the 
BC domain to the CT domain. While not directly involved, 
the presence of free biotin has been shown to have a stimula-
tory effect on both the ADP phosphorylation and bicarbon-
ate-dependent ATP cleavage reactions. Consequently, the 
oxamate-induced removal of the tethered biotin from the BC 
domain explains the apparent inhibition by oxamate.  
Nucleoside and Nucleotide Inhibitors 
 While MgATP is the physiological nucleotide substrate 
for the pyruvate carboxylation reaction of PC (Km of the or-
der of 40-60 μM), MgdATP is also an effective substrate, 
with a Km of approximately 70 μM [33, 62]. MgGTP, 
MgUTP, MgCTP, MgTTP and MgITP (Fig. 4) have all been 
reported to act as competitive inhibitors of pyruvate carboxy-
lation with respect to MgATP, giving Ki values in the range 
of 0.7-0.9 mM [62]. However, Scrutton and Utter [33] re-
ported them to be non-competitive inhibitors of the 
[32P]ATP:ADP isotope exchange reactions with chicken liver 
PC. As McClure et al. [62] pointed out, the non-competitive 
nature of the inhibition may have been due to the fact that 
free nucleotides, rather than those complexed with Mg2+, 
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were used in the inhibition studies. Interestingly, the Ki val-
ues reported by Scrutton and Utter [33] are approximately an 
order of magnitude lower than those reported by McClure et 
al. [62], suggesting that un-complexed nucleotides may bind 
with a higher affinity than the MgNTP complexes.  
 Both 5’-AMP and 3’, 5’-cyclic AMP have been reported 
to be competitive inhibitors with respect to MgATP [62] 
with PC isolated from rat liver (Ki = 1.3 mM and 1.0 mM, 
respectively). Based on these steady-state kinetic studies, it 
was proposed that that the reduction in the number of phos-
phoryl groups, as compared to ATP, had a greater effect on 
the nucleotide binding affinity than the positioning of the ?-
phosphate did. In light of these results, it is somewhat sur-
prising that adenosine is an extremely potent competitive 
inhibitor with respect to MgATP [62, 63] (Ki = 0.08-0.09 
mM). In the R. etli PC holoenzyme structure with ATP-?-S 
bound in the BC domain, there are seven potential hydrogen-
bonding interactions between the adenosine portion of ATP-
?-S and residues in the active site (Fig. 5) [19]. These ob-
served interactions, combined with the adenosine inhibition 
kinetics, support the proposal that a significant amount of the 
nucleotide binding energy in the BC domain comes from 
interactions between the active site residues and the adeno-
sine moiety of MgATP. Therefore, it can be argued that the 
negatively charged phosphoryl group of 5’-AMP or 3’-AMP 
introduces unfavorable electrostatic interactions within the 
active site that result in the decreased affinity of PC for these 
molecules as compared to adenosine. In another study, 5’-
AMP (Ki = 9.3 mM) and 3’-AMP (Ki = 13 mM) were both 
found to be non-competitive inhibitors of chicken liver PC 
[33], suggesting that in this case the nucleotides were bind-
ing with low affinity to a site outside the normal substrate 
binding site, possibly part of the acetyl CoA binding site. 
 Analogues of ATP, such as ATP-?-S which cannot act as 
a substrate, have been used in structure-function studies of 
PC [19]. The Mg2+-complex of the fluorescent ATP ana-
logue, formycin A-5’-triphosphate (MgFTP), is a competi-
tive inhibitor of chicken liver PC with respect to MgATP (Ki 
= 50 μM) [64]. However, sheep liver PC can utilize MgFTP 
as a substrate for pyruvate carboxylation, albeit with a kcat 
that is one-twentieth of that with MgATP as a substrate and a 
Km one-third of that for MgATP [64]. Since binding to PC 
enhances the fluorescence of MgFTP approximately 2-fold, 
FTP and FDP have been extensively used to study the pre-
steady state kinetics of nucleotide binding to PC in stopped-
flow experiments [65, 66]. The second-order binding rate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Structures of the various nucleotide and nucleoside inhibitors of PC. 
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constant of MgFTP was determined to be 2.6 ? 106 M-1 s-1 
and the dissociation rate constant was 82 s-1 in experiments 
using chicken liver PC [66]. The fluorescence of PC-bound 
MgFTP has also been used to measure the effects of other 
substrates and activators on nucleotide binding [66]. 
 Analogues of ADP have also been used to probe the 
mechanism of the BC domain. Ashman and Keech [58] 
found that ?, ?-methylene adenosine diphosphate 
(Ap(CH2)p) and adenosine 5’-phosphosulfate (APS) were 
competitive inhibitors for pyruvate carboxylation with re-
spect to MgATP in reactions catalysed by sheep kidney PC. 
The Ki (0.58 mM) determined for Ap(CH2)p was nearly 
three times lower than that of MgADP, indicating that the 
enzyme had a high affinity for this analogue. While APS 
also exhibited competitive inhibition with respect to 
MgATP, the Ki value of 3 mM signified the enzyme had a 
much lower affinity for the analogue. Additionally, it was 
determined that PC would not catalyse the phosphorylation 
of these analogues in the full reverse reaction. Similar to 
conclusions drawn by McClure [62] these data strongly sug-
gest that substitution at the ?, ? position of ADP is less criti-
cal for catalysis than substitutions at the position of bond 
cleavage/formation.  
INHIBITION OF THE CARBOXYL TRANSFERASE 
DOMAIN 
 In the CT domain, carboxybiotin is decarboxylated and a 
strictly conserved Thr residue is proposed to facilitate the 
transfer of a proton from pyruvate to biotin, thereby forming 
the highly nucleophilic enol-pyruvate [23]. Pyruvate ana-
logues and several dicarboxylic acids and their derivatives 
have been shown to be specific, reversible inhibitors of the 
carboxyl transfer step, usually through interactions with the 
Mn2+- or Zn2+-metal centre contained in the CT domain ac-
tive site.  
Oxamate 
 A potent inhibitor of lactate dehydrogenase [67], ox-
amate is a structural analogue of pyruvate which binds in the 
CT domain and induces the movement of the tethered biotin 
from the BC domain to the CT domain [37]. Furthermore, 
oxamate stimulates the decarboxylation of carboxybiotin, 
allowing for the examination of the steady-state kinetics of 
the reverse reaction of the CT domain in isolation from reac-
tions occurring in the BC domain [23, 68]. 
 Using chicken liver PC and monitoring the steady-state 
kinetics of pyruvate carboxylation with the malate dehydro-
genase coupled assay system, Scrutton et al. [69] determined 
that oxamate was a non-competitive inhibitor with respect to 
pyruvate in the overall pyruvate carboxylation reaction (Ki = 
1.6 mM). Previous pulsed NMR experiments examined the 
effect of oxamate on the relaxation rate of water protons co-
ordinated to the paramagnetic Mn2+-metal centre in the CT 
domain of PC from chicken liver mitochondria [35]. In this 
way, the coordination of substrates, inhibitors and products 
to the paramagnetic metal-center could be determined, al-
lowing for the direct examination of the inhibition kinetics. 
Based on the decreased enhancement of the water protons 
relaxation rate, due to their displacement by the substrate 
analogue inhibitors, oxamate was proposed to chelate to the 
Mn2+-metal centre in the CT domain. Uncompetitive ox-
amate inhibition with respect to pyruvate was observed for 
the pyruvate carboxylation reaction, but the inhibition was 
competitive when determined as a function of oxaloacetate 
for the reverse reaction. From the analysis of the proton re-
laxation data and the effect of oxamate on PC inactivation by 
avidin, a dissociation constant of KD = 1.45 mM was deter-
mined for the oxamate-enzyme complex. Direct coordination 
of oxamate to the Mn2+-metal centre, as suggested by the 
pulsed NMR experiments, would be expected to give com-
petitive inhibition patterns with respect to pyruvate, as ox-
amate would presumably prevent the coordination and sub-
sequent enolization of pyruvate. The uncompetitive nature of 
the inhibition could possibly be explained if oxamate forms 
an enzyme-inhibitor complex where the carboxylation of 
biotin is kinetically insignificant and pyruvate will only in-
teract appreciably with the enzyme once biotin is carboxy-
lated. Although it is difficult to envision how oxamate pre-
vents the carboxylation of the biotin at low concentrations, 
the movement and requisition of the tethered biotin to the CT 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Model of part of the active site of the CT domain of Rhizobium etli PC showing the potential binding interactions between ATP-?-S 
and residues in the active site. Reproduced with from [19]. 
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domain, induced by the coordination of oxamate to Mn2+, 
may be faster than the partially rate-limiting carboxylation 
reaction in the BC domain. 
 To assess the physiological relevance of oxamate inhibi-
tion of PC on the rates of hepatic gluconeogenesis, Martin-
Requero and co-workers analysed the effect of added ox-
amate on the gluconeogenic flux and PC activity in perfused 
rat livers, isolated hepatocyte suspensions [70] and isolated 
rat liver mitochondria [71]. In these studies, the resulting 
concentrations of metabolic intermediates were used to de-
termine the effect of oxamate on gluconeogenesis, while the 
rate of pyruvate carboxylation was approximated from a de-
termination of H14CO3
- incorporation into the metabolites 
isolated from mitochondrial extracts. In perfused rat livers 
and isolated hepatocytes [70], the presence of oxamate re-
sulted in a decrease in the concentrations of all metabolites 
after pyruvate, indicating that the inhibitory effect on  
gluconeogenesis was due, in part, to the inhibition of PC. 
Oxamate was determined to be a competitive inhibitor of 
gluconeogenesis at concentrations of pyruvate less than 0.4 
mM and had little effect on glucose production at concentra-
tions of pyruvate greater than 0.4 mM. These results are 
somewhat surprising in light of studies performed with the 
isolated rat liver [62] and chicken liver enzymes (above), 
both of which showed an uncompetitive oxamate inhibition 
when pyruvate was the varied substrate. The discrepancy 
between the type of inhibition exerted by oxamate in the 
isolated enzymes and in the perfused liver studies suggested 
that oxamate may be inhibiting not only PC but also another 
enzyme whose mitochondrial function is directly related to 
pyruvate utilization in gluconeogenesis. 
 In an extension of these initial studies, oxamate was de-
termined to exhibit a mixed-type inhibition pattern with re-
spect to pyruvate in isolated mitochondria from rat liver [71]. 
Similar to the previous study, oxamate inhibited pyruvate 
carboxylation by approximately 40% at low pyruvate con-
centrations, but had no discernible effect on the net glu-
coneogenic flux at concentrations of pyruvate greater than 
0.4 mM. Varying HCO3
- and determining the rates of pyru-
vate carboxylation in the presence of oxamate resulted in a 
non-competitive inhibition pattern. The lack of substantial 
inhibition at high concentrations of pyruvate and competitive 
inhibition with respect to pyruvate at low concentrations 
strongly suggested that oxamate inhibition of gluconeogene-
sis in the isolated mitochondria resulted from the non-
competitive inhibition of PC and the competitive inhibition 
of the mitochondrial pyruvate translocator protein, which 
facilitates pyruvate transport across the mitochondrial mem-
brane [71].  
Oxalate 
 Oxalate, an inhibitor of both lactate dehydrogenase [72] 
and transcarboxylase [73], was also found to be an effective 
inhibitor for PC from a variety of sources. For example, ox-
alate was a non-competitive inhibitor with respect to HCO3
- 
(Ki = 60-300 ?M [62]) in rat liver PC and a non-competitive 
inhibitor with respect to pyruvate (Ki = 70 ?M) for PC iso-
lated from yeast [74] as well as PC from rat liver (Ki = 50-
130 ?M [62]) and chicken liver (Ki = 12 ?M) [69]. Barden 
and co-workers [75] extended the initial kinetic studies of 
oxalate inhibition of chicken liver PC. Steady-state kinetic 
analysis determined that, while the inhibition was uncom-
petitive with respect to pyruvate for the pyruvate carboxyla-
tion reaction, oxalate inhibition was competitive with respect 
to oxaloacetate for the decarboxylation reaction, confirming 
results previously obtained from pulsed NMR experiments 
[35]. Avidin inactivation studies in the presence of oxalate 
[35] provided a dissociation constant of 8.9 ?M for the ox-
alate-PC complex, nearly three orders of magnitude lower 
than that determined for oxamate, indicating that the biden-
tate chelation of oxalate to the Mn2+-metal centre most likely 
increases the affinity of the enzyme for the inhibitor. 
McClure [62] probed the effect that the inhibition of the CT 
domain with oxalate had on the affinity for substrates in the 
BC domain by studying the steady-state kinetics of the pyru-
vate carboxylase reaction catalyzed by PC from rat liver. As 
expected, oxalate was also found to be a non-competitive 
inhibitor with respect to MgATP.  
 Similar to oxamate, oxalate also inhibits gluconeogenesis 
in isolated mitochondria and hepatocytes. Dennis et al. [76]  
determined that oxalate had no inhibitory effect on pyruvate  
transportation into the mitochondria; therefore the inhibition  
of glucose production was presumably due to the direct  
inhibition of PC by oxalate. In subsequent studies, both  
Yount and Harris [77] and Tonon and co-workers [78] found  
that the infusion of isolated rat hepatocytes with oxalate  
significantly inhibited hepatic gluconeogenesis from alanine,  
pyruvate and lactate as determined from the concentrations  
of the metabolic intermediates. In bicarbonate-deficient  
media, where PC activity became completely rate-limiting,  
the inhibition of glucose production by oxalate was even  
more apparent, further supporting the idea that oxalate was  
directly inhibiting PC activity [77]. The addition of 100 ?M  
of oxalate reduced the steady-state levels of oxaloacetate by  
48% in rat liver cells [79] and physiological concentrations  
of oxalate (50-100 ?M) were found to partially impair  
the mitochondrial metabolism of pyruvate, resulting in  
decreased anaplerosis due to the oxalate inhibition of PC  
[80].  
Pyruvate Derivatives 
 Many of the derivatives of pyruvate, including fluoro and 
chloropyruvate, not only act as carboxyl acceptors for the 
PC-catalyzed carboxylation reaction but can also act as ef-
fective, specific inhibitors of the carboxyl transfer reaction. 
Scrutton et al. [69] examined the inhibition of the carboxyl 
transfer reaction using fluoropyruvate (Ki = 0.17 mM) and 
phenylpyruvate (Ki = 0.48 mM). Both analogues were non-
competitive inhibitors with respect to pyruvate when the 
initial rates of oxaloacetate formation were determined. 
Pulsed NMR studies [35] suggested that fluoropyruvate in-
hibited the carboxyl transfer in a mechanism similar to ox-
amate and oxalate where the direct coordination of the ana-
logue to the cationic-metal centre partially prevented pyru-
vate coordination and subsequent enolization.  
 In rat brain mitochondria [81], fluoropyruvate was de-
termined to inhibit anaplerosis by not only the direct inhibi-
tion of PC, but also by lowering the available concentration 
of acetyl CoA in the mitochondria. The addition of 0.5 mM 
of fluoropyruvate resulted in a 95% inhibition of cerebral PC 
activity as determined from the initial rate of oxaloacetate 
formation using H14CO3
-. In order to determine if the potent 
inhibition of the mitochondrial activity was due solely to the 
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inhibition of PC, the activities of the isolated enzyme, treated 
with varying concentrations of fluoropyruvate were deter-
mined. The competitive inhibition of the isolated PC by 
fluoropyruvate was mild; only a 47 % inhibition of PC activ-
ity was observed with the addition of 5 mM of fluoropyru-
vate which accounted for only a fraction of the inhibition 
observed in the intact cerebral mitochondria. The addition of 
10 ?M of acetyl CoA to the reactions completely reversed 
the inhibition of pyruvate carboxylation at low concentra-
tions of fluoropyruvate. It is possible that, in the cerebral 
mitochondria, the inhibitory effect of fluoropyruvate mani-
fests itself in two ways, namely through the direct, competi-
tive inhibition of PC and through the formation of fluoroace-
tyl CoA, which thereby limits the availability of the potent 
PC activator, acetyl CoA.  
 The investigation of hepatic gluconeogenesis inhibition 
by fluoro- and chloropyruvate, chloroacetic acid and 3-
chloro-1,2-propanediol (CPD), a carcinogenic chloropro-
panol, in rat liver slices demonstrated that chloropyruvate 
was a more potent inhibitor of PC activity than the other 
analogues examined [82]. High doses of CPD, which is pro-
posed to be metabolized to either chloropyruvate or 
chloroacetic acid also inhibited gluconeogenesis. The addi-
tion of 10 mM of chloropyruvate resulted in the nearly com-
plete inhibition of glucose production (> 95%), compared to 
85% and 54% inhibition using 10 mM of fluoropyruvate and 
chloroacetic acid, respectively. Chloropyruvate was also a 
more potent inhibitor as compared to CPD, although a 45% 
reduction in PC activity was observed in the presence of 10 
mM of CPD. Further experiments confirmed that the inhibi-
tion of gluconeogenesis was in fact due to the direct modula-
tion of PC activity in the rat liver slices [82].  
 PC isolated from Thiobacillus novellus, a methylotrophic 
chemiolithautotroph, is allostericaly activated by acetyl CoA 
and inhibited by hydroxypyruvate [83]. Aspartate, glutamate 
and other dicarboxylic acids, such as ?-ketoglutarate, had no 
effect on oxaloacetate production [84]. The addition of 2 
mM of hydroxypyruvate resulted in a 35% reduction in py-
ruvate carboxylating ability. Initial rate studies determined 
that this pyruvate derivative was a non-competitive inhibitor 
with respect to HCO3
- (Ki = 7.1 mM), MgATP (Ki = 5.5 
mM), and, surprisingly, pyruvate (Ki = 5.4 mM), indicating 
that the binding of these substrates did not significantly af-
fect the enzyme’s affinity for hydroxypyruvate. It is interest-
ing to note that hydroxypyruvate was also an uncompetitive 
inhibitor with respect to acetyl CoA (Ki = 3.6 mM) and re-
duced the Hill coefficient for acetyl CoA binding 2-fold. The 
inhibition patterns observed with respect to acetyl CoA sug-
gested that the reversible binding of the activator to the en-
zyme increased the affinity of the inhibitor for PC. While 
somewhat uncommon that PC from Thiobacillus novellus is 
only mildly inhibited by hydroxypyruvate, it is further evi-
dence that substrate derivatives, like fluoropyruvate, chloro-
pyruvate and hydroxypyruvate, appear to down-regulate PC 
gluconeogenic activity in most cases, rather than completely 
inhibiting the enzyme.  
INHIBITION BY UNIVALENT AND DIVALENT 
CATIONS 
 In the PC-catalysed pyruvate carboxylation reaction, 
there appears to be an absolute mechanistic requirement of 
two Mg2+ ions, which are sequestered into the BC domain 
active site via the complexation to ATP [19]. There is also a 
need for a divalent cation in the CT domain, generally Mn2+ 
or Zn2+, which is proposed to act as a Lewis acid and pro-
mote the enolization of pyruvate [23, 69]. Although PC from 
various sources exhibit similar catalytic properties, there is a 
wide difference in responses to activation and inhibition by 
various cations including Ca2+, Zn2+, Mn2+, Li2+ and Na+. 
While this review does not attempt to be comprehensive in 
its discussion of the inhibition of PC by univalent and diva-
lent cations, some of the more detailed studies of the effects 
of these inhibitors will be discussed.  
 Zn2+, Cu2+ and Cd2+ are potent inhibitors of chicken liver 
PC [69], most likely due to the formation of inactive metal-
ATP complexes. Similarly, pyruvate carboxylation catalyzed 
by PC from baker’s yeast [85] is effectively inhibited by the 
addition of Sr2+, Co2+, Cu2+, and Sn2+. Interestingly, the addi-
tion of 5 ?M of Na+ resulted in a 60% decrease in the rates 
of the Pi:ATP exchange reaction in yeast PC, indicating that 
the inhibitory effect of the monovalent cation was on the 
biotin carboxylation reaction rather than the carboxyl trans-
fer to pyruvate. Mn2+ was inhibitory in rat liver PC [86] at 
concentrations above 2 mM but, while appreciable concen-
trations of free Mn2+ inhibited pyruvate carboxylation, the 
presence of Mg2+ fully restored PC activity. Zn2+ was also a 
potent inhibitor of rat liver PC [86], where the addition of 
0.06 mM of ZnSO4 completely and irreversibly inactivated 
the enzyme. Further experiments suggested that even in the 
presence of saturating Mg2+, the two Zn2+ ions remained co-
ordinated to the enzyme. Unlike chicken liver PC, which is 
activated by the addition of Co2+ [87], rat liver PC is inhib-
ited by the cation [86].  
 Barden and Scrutton [88] extended the initial studies of 
cation inhibition of PC from chicken liver. While a majority 
of univalent cations, including K+, Rb+ and Cs+, were activa-
tors of the overall pyruvate carboxylation reaction, Li+ inhib-
ited not only the K+-stimulated activity, but also PC activity 
in the absence of any activators. Li+ was determined to be a 
non-competitive inhibitor (Ki = 42 ± 3 mM) with respect to 
K+ for the K+-stimulated pyruvate carboxylation, suggesting 
that Li+ is coordinating to sites inaccessible to K+.  
 Physiologically, while the inhibition of rat liver PC by 
Co2+ and Mn2+ appears to be of little consequence, the inhibi-
tion of PC activity by Ca2+ as observed in isolated rat liver 
[86, 88] and in intact rat liver mitochondria [89] may be a 
means by which the mitochondria regulates gluconeogenesis. 
PC activity in the intact mitochondria was determined by 
measuring the release of 14CO2 from pyruvate-1-
14C, which 
allowed for the determination of both PC and pyruvate de-
hydrogenase activity, as well as directly measuring the con-
centrations of the TCA cycle intermediates. Based on this 
investigation, Kimmich and Rasmussen [89] determined that 
Ca2+ was a potent and specific inhibitor of PC in the intact 
mitochondria with the addition of 100 ?M of Ca2+ resulting 
in a 75% loss of PC activity. The extent of Ca2+ inhibition 
was dependent on the Mg2+/Ca2+ ratio, prompting further 
studies by Wimhurst and Manchester [86] which examined 
the inhibitory effect of Ca2+ at varying concentrations of 
Mg2+ (3.2 and 8.0 mM) using isolated rat liver PC. Ca2+ was 
a competitive inhibitor with respect to Mg2+ (Ki = 0.38 mM), 
suggesting the displacement of Mg2+ in the ATP binding site 
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with Ca2+. PC was less susceptible to Ca2+ inhibition when 
Mn2+ was used instead of Mg2+, resulting in only 20% inhibi-
tion in the presence of 1 mM of Ca2+ as opposed to 60% in-
hibition when Mg2+ was used as the enzyme activator [86]. 
The interplay between Ca2+ inhibition and Mg2+ activation of 
PC suggests that changes in the intracellular concentrations 
of these ions may have a role in regulating gluconeogenesis 
via the direct inhibition or activation of PC [89]. 
INHIBITORS OF THE ALLOSTERIC SITE 
 Acetyl Coenzyme A is an allosteric activator of many PC 
enzymes. Recent structural studies reveal that the acetyl CoA 
binding site is centered in an allosteric domain, also referred 
to as the tetramerization domain, which is remote from either 
of the two active sites [19, 20]. A number of PC inhibitors 
exert their influence on the enzyme through interactions in 
the allosteric domain, either by competing with acetyl-CoA 
and/or by modulating the cooperativity of acetyl CoA bind-
ing. 
Dicarboxylate Allosteric Inhibitors: Aspartate, Gluta-
mate and ?-Ketoglutarate 
 Aspartate, ?-ketoglutarate and glutamate are allosteric 
inhibitors of PC that, under physiological conditions, provide 
regulatory feedback inhibition in response to the increased 
production of TCA cycle intermediates. Aspartate serves as 
an allosteric inhibitor of microbial and fungal PC, while glu-
tamate serves this same role in PC isolated from vertebrate 
sources [90-93]. 
Aspartate Inhibition of Microbial PC 
 PC from Saccharomyces cerevisiae is activated by acetyl 
CoA and inhibited by L-aspartate in an allosteric manner. In 
PC from S. cerevisiae, as in most PC enzymes inhibited by 
aspartate, the mode of inhibition occurs through an antago-
nistic effect on the activation by acyl CoA derivatives [93-
97]. Aspartate increases the Hill coefficient for acetyl CoA 
and, conversely, acetyl CoA increases the Hill coefficient for 
aspartate [95-97]. The aspartate inhibition kinetics are com-
plex, typically exhibiting non-classical behaviour. PC from 
S. cerevisiae is inhibited by aspartate in the presence of the 
activators acetyl CoA or palmitoyl CoA, with the addition of 
10 mM aspartate resulting in a 70- to 80-fold increase in the 
activator concentration required for half-maximal activation 
[96]. In fungi, the aspartate allosteric binding site appears to 
be distinct from the site of acetyl CoA binding, despite the 
observed competitive inhibition of acetyl CoA by aspartate 
[95, 98]. The suggestion of independent binding sites is sup-
ported by the fact that the loss of activation by acetyl CoA 
upon incubation of PC with trinitrobenzene sulfonate does 
not correlate with any concomitant loss of inhibition by as-
partate [93, 98, 99]. PC from the fungus Aspergillus nidulans 
has also been shown to be partially inhibited by aspartate 
[98, 100]]. Aspartate is a competitive inhibitor with respect 
to acetyl CoA and is non-competitive with respect to 
MgATP and pyruvate [98], consistent with a binding site 
located in the allosteric domain of the enzyme. Aspartate has 
an IC50 = 0.6 mM and displays positive cooperativity (Hill 
coefficient = 2.1) in the absence of acetyl-CoA. Contrary to 
the effect of acetyl CoA on the cooperativity of aspartate in 
most other PC enzymes, the Hill coefficient is reduced in PC 
from A. nidulans in the presence of 20 μM acetyl CoA. Both 
aspartate and glutamate inhibit the cytosolic isoenzyme of 
PC from Rhizopus arrhizus, though it is likely that glutamate 
exerts its affect by acting as an analogue of aspartate [101]. 
The reduced stringency in discriminating between aspartate 
and glutamate appears to be unique to R. arrhizus PC.  
 Bacterial PC enzymes are also reported to be inhibited by 
L-aspartate, though there is significant variation among the 
bacterial enzymes. PC from Pseudomonas citronellis [102, 
103], Pseudomonas fluorescens [104], Methanosarcina 
barkeri [105] and Azotobacter vinelandii [106] are arranged 
in an (??)4 structure where two polypeptide chains contrib-
ute to the protomer. PC with this (??)4 structure are neither 
activated by acetyl CoA nor inhibited by aspartate. Con-
versely, bacterial PC enzymes that consist of four identical 
subunits (?)4, similar to the arrangement in the PC enzymes 
isolated from eukaryotic sources, are affected by the pres-
ence of acetyl CoA and aspartate. For example, the bacterial 
(?)4 enzymes isolated from thermophilic Bacillus [93], Ar-
throbacter globiformis [107], Rhodobacter capsulatus [108] 
and Sinorhizobium meliloti [109] are allosterically activated 
by acetyl CoA and allosterically inhibited by aspartate. This 
suggests that the aspartate binding site in the (?)4 PC en-
zymes is most likely located in the relatively small allosteric 
domain, near the acetyl CoA binding site [19, 21]. While the 
binding site for acetyl CoA has been identified in X-ray crys-
tal structures of bacterial (?)4 enzymes [19, 21], the precise 
binding site for aspartate has yet to be delineated. The con-
centration of aspartate required for significant inhibition of 
PC is relatively high (~5 to 10 mM), but it has been sug-
gested that these concentrations are, nonetheless, physiologi-
cally relevant [95]. 
Glutamate Inhibition of Vertebrate PC 
 While PC isolated from vertebrate sources is insensitive 
to aspartate, they are allosterically inhibited by L-glutamate 
[90, 110, 111] Scrutton and White [99] reported approxi-
mately 50% inhibition of the acetyl CoA activated rate of 
oxaloacetate synthesis in the presence of 5 mM glutamate for 
PC isolated from both chicken liver and rat liver. No inhibi-
tion was observed in the presence of 5 mM aspartate. Com-
parable concentrations of glutamate have been measured in 
rat liver [112, 113], suggesting that glutamate provides a 
physiological mechanism for the negative feedback regula-
tion of PC activity. Glutamate appears to be a non-classical, 
non-competitive inhibitor with respect to acetyl CoA with  
an apparent Ki of 3.8 mM for chicken liver PC and 4.7 mM 
for rat liver PC. The Hill coefficient is insensitive to acetyl 
CoA and approximates to a value of 1 at all concentrations 
of acetyl CoA [90]. For both the chicken and rat liver PC, 
glutamate acts as a competitive inhibitor with respect to  
pyruvate, a non-competitive inhibitor with respect to 
bicarbonate and an uncompetitive inhibitor with respect to 
MgATP [90]. A similar pattern of inhibition is observed with 
respect to the substrates of human liver PC [111]. 
Inhibition by ?-Ketoglutarate  
 Allosteric inhibition of PC by ?-ketoglutarate has been 
characterized for PC enzymes from a number of sources, 
including avian liver [90], the fungi A. nidulans and S. cere-
visiae [93, 98], and the prokaryotes Bacillus [93] and 
Rhodobacter capsulatus [108]. Modest inhibition (~15%) 
has also been reported in PCs isolated from the methanogens 
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Methanosarcina barkeri [105] and Methanobacterium ther-
moautotrophicum [114]. Unlike PC inhibition by glutamate 
and aspartate, inhibition by ?-ketoglutarate appears to be 
widely distributed, but not universal. Several dicarboxylic 
and tricarboxylic acids are inhibitory for PC from R. arrhizus 
with 2-oxoadipate exhibiting many similar characteristics to 
?-ketoglutarate [101]. Inhibition properties suggest that 2-
oxoadipate and aspartate inhibit the enzyme by binding to 
independent regulatory sites. PC from A. nidulans has been 
shown to be inhibited by the binding of ?-ketoglutarate at a 
distinct allosteric site removed from the site of action for L-
aspartate. [91, 98, 100]. Similarly, PC from avian liver is 
also inhibited by ?-ketoglutarate binding at a distinct inhibi-
tory site from that of glutamate [90]. The ?-ketoglutarate 
inhibition has been extensively characterized in chicken liver 
PC, where a Hill coefficient of 1.5 and an apparent Ki of 3 
mM has been reported [90]. As the acetyl CoA concentration 
is increased to saturation, the Hill coefficient for ?-
ketoglutarate increases to ~3. Conversely, the concentration 
of ?-ketoglutarate has no effect on the Hill coefficient for 
acetyl CoA. The inhibitory site for ?-ketoglutarate in 
chicken liver is also proposed to be distinct from the acetyl 
CoA binding site, since ?-ketoglutarate inhibition is insensi-
tive to reagents that eliminate acetyl CoA activation [90]. 
The presence of separate allosteric binding sites for acetyl 
CoA, ?-ketoglutarate and glutamate in the chicken liver en-
zyme led Scrutton and White [90] to propose that the physio-
logical ratio of these metabolites permits regulatory control 
over chicken liver PC activity in the mitochondria [115]. 
Chlorothricin 
 Chlorothricin is a macrolide-type antibiotic produced by 
Streptomyces antibioticus strain Tü 99 [116, 117]. It is a 
freely reversible competitive inhibitor of PC from Bacillus 
stearothermophilus with an apparent Ki of 173 μM that in-
creases the Hill coefficient for acetyl CoA from 2 to 3 [118]. 
Chlorothricin’s effect on Bacillus stearothermophilus PC 
activity is limited to its antagonistic interaction with acetyl 
CoA, as it does not inhibit PC in the absence of acetyl CoA 
[118]. However, chlorothricin does inhibit both Azotobacter 
vinelandii PC and rat liver PC in the presence and absence of 
acetyl CoA [119]. Chlorothricin is noncompetitive with re-
spect to both MgATP and pyruvate and suppresses substrate 
activation by pyruvate while promoting MgATP substrate 
inhibition [118, 119]. These results lead Schindler and Zah-
ner [118] to propose that chlorothricin binding to PC stabi-
lizes a less active conformation of the enzyme. 
 Chlorothricin also reversibly inhibits PC from Bacillus 
subtilis, rat liver, chicken liver and Azotobacter vinelandii 
[118-120], with IC50 values ranging from 0.12 to 0.50 mM. 
The antibiotic has a greater affect on PC enzymes that have a 
more pronounced sensitivity to acetyl CoA activation. The 
aglycone of chlorothricin, or the chlorothricolide methyl 
ester, is also inhibitory against all enzymes from B. 
stearothermophilus, A. vinelandii, chicken liver and rat liver, 
though to a lesser degree [119]. The ?-methyl rhamnoside 
portion of chlorothricin did not display any inhibitory prop-
erties, indicating that the aglycone portion of the molecule is 
the primary site of interaction. It is noteworthy that intact 
chlorothricin displays cooperative inhibition of the acetyl 
CoA activation in the vertebrate liver PC enzymes, while the 
aglycone portion of chlorothricin does not exhibit coopera-
tivity [119]. Chlorothricin is a non-competitive inhibitor with 
respect to acetyl CoA in PC isolated from vertebrate liver, 
and is a non-competitive inhibitor with respect to all sub-
strates [119]. Chlorothricin not only protects chicken liver 
PC against cold inactivation, but also protects rat liver PC 
against inactivation by trinitrobenzenesulfonate at the allos-
teric activator site, though in neither case does it confer the 
same degree of protection as does acetyl CoA [119, 121]. 
Despite these findings, Schindler and Scrutton [119] argue 
against chlorothricin binding in the allosteric activator bind-
ing site of vertebrate PC on the basis of its non-competitive 
inhibition of acetyl CoA activation and its lack of sensitivity 
to inhibition of rat liver PC that has an inactivated allosteric 
activator binding site. While there are no other reports of PC 
inhibition by other macrolide-type antibiotics, NMR studies 
probing the inhibitory effects of the polyene antibiotic, am-
photericin B, on glucose metabolism in S. cerevisiae suggest 
that it may function by reducing PC activity [122]. 
Benzoate 
 Griffith et al. first demonstrated that PC activity is inhib-
ited by sodium benzoate in the intact mitochondria of rat 
liver [123]. Even though benzoate is converted to benzoyl 
CoA in the rat liver [113, 123, 124] benzoyl CoA does not 
directly compete with acetyl CoA activation in PC from mi-
tochondrial extracts [123, 124]. Rather, benzoate exerts its 
inhibitory effect on PC through its conversion to benzoyl 
CoA and subsequent depletion of the pool of available coen-
zyme A and acetyl CoA [123]. The addition of 1 mM sodium 
benzoate resulted in the reduction of intracellular acetyl CoA 
concentration from 0.5 mM (a concentration greater than Ka 
) to 0.1 mM (a concentration less than Ka) [113] . 
Phenylacetate/Phenylacetyl CoA 
 Bahl et al. [125] first reported the suppression of liver 
gluconeogenesis by the inhibition of PC using phenylacetic 
acid. HPLC analysis of rat liver mitochondrial preparations 
demonstrated that phenylacetate was largely converted to 
phenylacetyl CoA in vivo. Kinetic investigations of the puri-
fied rat liver PC demonstrated that, at high acetyl CoA con-
centrations (> 100 μM) phenylacetyl CoA inhibits PC while 
the precursor phenylacetate has no inhibitory effect on the 
enzyme activity. At low acetyl CoA concentrations, pheny-
lacetyl CoA inhibited the enzyme in the 5 to 50 μM range. 
The report of phenylacetyl CoA inhibition by Bahl et al. 
conflicts with earlier reports that both phenylacetyl CoA and 
benzoyl CoA are weak activators of PC from rat liver and 
thermophilic Bacillus [93, 110]. It is possible, therefore, that 
the mechanism of inhibition also includes the sequestration 
of mitochondrial CoA pools, similar to the proposed mode of 
benzoate inhibition. Phenylacetate has been used as an effec-
tive inhibitor to study the role of PC in GSIS in INS-1 cells 
[126, 127] and in the isolated pancreatic islets of rats [8, 
127]. 
Acyl CoA Analogues 
 Several studies have revealed that a broad spectrum of 
acyl CoA analogues and acetyl CoA fragments will maintain 
low levels of allosteric activation for PC isolated from a va-
riety of microbial and vertebrate species, indicating that the 
allosteric site of the enzyme is relatively tolerant to modifi-
cations of acetyl CoA [21, 36, 93, 110, 128]. In chicken liver 
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PC, acyl CoA analogues that have acyl chain lengths less 
than 4 act as allosteric activators while the longer chain acyl 
CoA analogues act as allosteric, competitive inhibitors with 
respect to acetyl CoA. Increasing the acyl chain lengths from 
4 (valeryl CoA) to 10 (n-decanoyl CoA), resulted in in-
creases in both the IC50 and Hill coefficients [110]. Contrary 
to chicken liver PC, acyl CoA analogues of any length are 
activators of the rat liver and Bacillus PC enzymes [36, 93]. 
Carboxylated acyl analogues of acetyl CoA are competitive 
inhibitors of rat liver PC, chicken liver PC and Bacillus PC 
with respect to acetyl CoA. Of the carboxylated analogues 
examined, methylmalonyl CoA exhibits the highest degree 
of inhibition against both chicken liver and rat liver PC [36, 
110]. Furthermore, rat liver PC is also inhibited by succinyl 
CoA, maleyl CoA and glutaryl CoA [110].  
 Analogues of the diphosphoadenosine portion of acetyl 
CoA do not activate PC and, in fact, will act as competitive 
inhibitors with respect to acetyl CoA in PC from both rat and 
chicken liver PC [36, 110]. Unlike other acyl CoA ana-
logues, acetoacetyl CoA is a noncompetitive inhibitor of 
chicken liver PC with respect to all substrates. Surprisingly, 
acetoacetyl CoA is also a noncompetitive inhibtor with re-
spect to acetyl-CoA and, furthermore, the inhibition results 
in a decreased Hill coefficient for acetyl CoA activation in 
chicken liver PC [115, 129]. While acetoacetyl CoA is a 
much weaker inhibitor for rat liver PC and has no effect on 
the acetyl CoA Hill coefficient in rat liver PC [115] these 
data, nevertheless, suggest that acetoacetyl CoA binds at a 
unique allosteric site, though the physiological relevance of 
this effect is unclear  [115]. 
Sulfate 
 The role of the sulfate ion (SO4
2-) in chicken liver PC 
inhibition was investigated in detail by Scrutton and Fung 
[130]. Sulfate is a competitive inhibitor of chicken liver PC 
with respect to acetyl CoA, exhibiting a Ki of 1.0 to 1.3 mM 
at pH 7.8. The anion appears to exert its affect by interacting 
at the allosteric site of chicken liver PC as determined from 
its competitive inhibition with acetyl CoA, its noncompeti-
tive inhibition with respect to MgATP, inorganic phosphate 
(oxaloacetate decarboxylation assay) and bicarbonate and its 
uncompetitive inhibition with respect to pyruvate. There is 
little cooperative effects observed for SO4
2- inhibition of PC, 
though the Hill coefficient increases slightly with increasing 
concentrations of acetyl CoA. While both (NH4)SO4 and 
K2SO4 increase the rate of inactivation of chicken liver PC 
by N-ethylmaleimide, the mechanistic basis of the increased 
rate of inactivation remains unclear [131]. The competitive 
inhibition of SO4
2- with respect to acetyl CoA observed in 
PC isolated from chicken liver appears to be a unique prop-
erty of the avian enzyme since sulfate inhibition has not been 
observed in PC enzymes isolated from other sources, includ-
ing rat liver, rat brain, S. cerevisiae and Pseudomonas citro-
nellis [130, 132, 133].  
CONCLUDING REMARKS 
 Much of the research focusing on the inhibition of pyru-
vate carboxylase that has been undertaken over the last forty 
or so years has greatly facilitated a preliminary understand-
ing of the overall PC mechanism. With the recent solution of 
several structures of the enzyme, the results of these inhibi-
tion studies can now be fully realized and re-evaluated in 
light of the structure-function relationships that are currently 
being investigated. Since PC has been shown to be a major 
bottleneck in the commercial production of amino acids, the 
development of small molecule effectors, which regulate 
enzymatic activity, may also be of importance in various 
industrial applications. [134]. Moreover, with the vast 
amount of available evidence correlating PC activity and  
the development of debilitating metabolic diseases, such as 
Type II diabetes, these initial inhibitor studies may provide 
valuable starting points for the design of drugs that modulate 
the activity of the enzyme for therapeutic purposes.  
ABBREVIATIONS 
PC = Pyruvate carboxylase 
BC = Biotin carboxylase 
CT = Carboxyl transferase 
BCCP = Biotin-carboxyl carrier protein 
Acetyl = Acetyl CoA 
Coenzyme A 
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